Skip to the main content

Acta medica Croatica : Časopis Akademije medicinskih znanosti Hrvatske, Vol. 66 No. 3, 2012.

Original scientific paper

THE EFFECTS OF TRIMETAZIDINE ON QT-INTERVAL PROLONGATION IN PATIENTS WITH CHRONIC KIDNEY DISEASE STAGE III-IV (PREDIALYSIS CRD)

DIANA BALENOVIĆ ; Department of Internal Medicine, Sisak General Hospital, Sisak, Croatia
INGRID PRKAČIN ; Merkur University Hospital, University Department of Internal Medicine, Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia
GORDANA CAVRIĆ ; Merkur University Hospital, University Department of Internal Medicine, Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia
I. HORVAT ; Department of Internal Medicine, Sisak General Hospital, Sisak, Croatia
DARKO POČANIĆ ; Merkur University Hospital, University Department of Internal Medicine, Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia
I. BAOTIĆ ; Merkur University Hospital, University Department of Internal Medicine, Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia

Full text: croatian pdf 76 Kb

page 153-155

downloads: 1.087

cite

Abstract

Prolonged QT interval is a predictor of cardiovascular mortality. It indicates delayed repolarization of ventricular myocardium and is considered a precursor of malignant cardiac arrhythmias and sudden cardiac death. Increased cardiovascular risk (CVR) in the presence of prolonged QT interval, corrected by heart rate (QTc), is attributed to ventricular electrical instability. Patients with chronic renal disease (CRD) usually die from sudden cardiac death before reaching the inal stage, inal chronic kidney disease (CRD stage V). We investigated whether patients with CRD stage III-V have prolonged QT interval, what are the possible causes of this extension, and whether in this patient population trimetazidine application may affect the reduction in QT prolongation. Our study showed one quarter of predialysis patients, mostly asymptomatic, to have QT prolongation, thus being at a higher risk of CV events. Introducing trimetazidine along with standard therapy can reduce the incidence of sudden cardiac death, and calculation of the QTc index would be a useful and economical method of screening and monitoring high risk patients.

Keywords

kidney disease; QT interval; sudden cardiac death; trimetazidine

Hrčak ID:

97324

URI

https://hrcak.srce.hr/97324

Publication date:

14.2.2013.

Article data in other languages: croatian

Visits: 2.311 *